NEW YORK – Codexis said Tuesday that it has inked a nonexclusive commercial and manufacturing license agreement for enzymes in its life science portfolio with Alphazyme, a unit of Maravai LifeSciences.
Financial details of the deal were not disclosed.
As part of the agreement, Codexis is licensing to Alphazyme its HiFi DNA polymerase, HiTemp reverse transcriptase, HiRev isothermal polymerase, and other enzymes that were in development for genomics and diagnostics applications. Codexis is also eligible to receive sales-based royalties.
Redwood City, California-based Codexis said the licensing agreement will enable it to divest its noncore assets following a strategic shift to focus on the growth of its pharmaceutical manufacturing business and Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform.
"This transaction enables Codexis to maintain its focus on maximizing our near-term commercial opportunities and strategic priorities," Kevin Norrett, the firm's chief operating officer, said in a statement. "This includes the growth of our pharmaceutical manufacturing business, increasing commercial adoption of the dsRNA ligase, and the build-out of our ECO Synthesis Innovation Lab to support manufacturing process development for our customers’ preclinical siRNA assets."
"This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to enhance the commercialization of Codexis’ portfolio of life science and diagnostic enzymes," Chad Decker, Alphazyme VP and general manager, said in a statement.